logo
logo
Vaxcyte, Inc.

Vaxcyte, Inc.

NASDAQ•PCVX
CEO: Mr. Grant E. Pickering M.B.A.
セクター: Healthcare
業種: Biotechnology
上場日: 2020-06-12
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
連絡先情報
825 Industrial Road, Suite 300, San Carlos, CA, 94070, United States
650-837-0111
vaxcyte.com
時価総額
$7.68B
PER (TTM)
-11.2
34.3
配当利回り
--
52週高値
$85.57
52週安値
$27.66
52週レンジ
46%
順位63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
8年ファンダメンタル
弱い • 1.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2018-2025

財務ダッシュボード

Q3 2025 データ

売上高

$0.00+0.00%
直近4四半期の推移

EPS

-$1.56+87.95%
直近4四半期の推移

フリーCF

-$155.35M+57.26%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

VAX-31 Advances to Phase 3 Selected VAX-31 High dose for adult Phase 3 pivotal study starting December 2025; topline data anticipated in 2026.
VAX-24 Infant Data Positive Final safety and immunogenicity results from VAX-24 infant Phase 2 study showed robust, dose-dependent immune responses.
Commercial Manufacturing Secured Agreement established with Thermo Fisher for long-term U.S. commercial supply commitment reaching up to $1.0B.
Significant Net Loss Widens Nine months net loss reached $520.1M USD, a 59.1% increase from $326.8M USD in prior period.

リスク要因

Highly Speculative Investment Company remains in clinical stages with no product revenue; incurred $1.91B accumulated deficit to date.
Substantial Future Funding Required Operations require substantial additional capital; existing cash reserves estimated to fund plans for at least 12 months.
Pipeline Development Uncertainty Vaccine candidates may fail in development or face material delays, severely harming commercial viability and prospects.
Third-Party Manufacturing Reliance Business depends on third-party CMOs for supply; interruptions or failure to meet cGMP standards adversely affect operations.

見通し

VAX-31 Phase 3 Execution Plan to initiate pivotal VAX-31 adult Phase 3 study in December 2025, with remaining Phase 3 studies planned for 2026.
Pipeline Prioritization Continues Strategic focus remains on PCV franchise advancement; VAX-A1 and VAX-GI programs are currently paused.
Managing Cash Runway Expect expenses to increase as clinical trials advance; cash position must support operations through at least 12 months.
Expanding Commercial Readiness Appointed new Chief Commercial Officer to lead global commercialization strategy, preparing for potential future product launches.

同業比較

売上高 (TTM)

PTC Therapeutics, Inc.PTCT
$1.78B
+97.5%
Alkermes plcALKS
$1.52B
+1.1%
Arrowhead Pharmaceuticals, Inc.ARWR
$1.09B
+4081.8%

粗利益率 (最新四半期)

Crinetics Pharmaceuticals, Inc.CRNX
100.0%
+0.0pp
Arrowhead Pharmaceuticals, Inc.ARWR
100.0%
+50.6pp
Avidity Biosciences, Inc.RNA
100.0%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
RNA$10.99B-18.3-37.7%2.3%
AXSM$9.14B-39.5-357.2%32.7%
ARWR$8.94B44.236.1%42.9%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
N/M
売上高の変動が大きい
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
0%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月24日
|
EPS:-$1.46
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月4日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.56+88.0%
    不明

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.22+10.9%
    不明

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.04+22.4%
    不明

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月25日|
    売上高: $0.00+0.0%
    |
    EPS: $-3.80+8.2%
    不明

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月5日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.83-8.8%
    不明

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月6日|
    売上高: $0.00+0.0%
    |
    EPS: $-1.10+57.1%
    不明

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $0.00+0.0%
    |
    EPS: $-0.85+21.4%
    不明

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月27日|
    売上高: $0.00+0.0%
    |
    EPS: $-4.14-20.3%
    不明